Scholarlink

<p>Hodgkin lymphoma (HL) is a B-cell neoplasm with a cure rate of 90%. Previous data on late morbidity in patients with HL cover the era of older treatment modalities. This real-world study consisted of 2912 patients diagnosed with HL between 2000 and 2019 in Finland and aimed to clarify the incidence of late-onset cardiopulmonary morbidity compared to matched controls. Patient data were collected from four nationwide Finnish healthcare registries. We reported a higher occurrence of coronary artery disease in patients aged &lt; 50 years at diagnosis than in controls (RR 3.80 (2.16–6.74), <i>p</i> &lt; 0001). Additionally, a higher incidence of both heart failure (RR 1.68 (1.28–2.21), <i>p</i> &lt; 0.001) and valvular heart disease (RR 1.80 (1.17–2.78), <i>p</i> = 0.006) was detected in patients aged ≥ 50 years at diagnosis than in the controls. Remarkably, in the &lt; 50 years age group, the incidences of pneumonia (RR 4.89 (3.58–6.71), <i>p</i> &lt; 0.001) and pulmonary embolism (RR 7.78 (2.75–21.95), <i>p</i> &lt; 0.001) were higher than those in the control group. In conclusion, with the current treatment modalities, late cardiopulmonary morbidity in long-term survivors remains a great challenge. A strategy for primary prevention and early detection of late toxicity remains crucial and a critical evaluation of current treatment practices is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Noora Hannuksela,
  • Outi Kuittinen,
  • Aino Rönkä,
  • Anna Anttalainen,
  • Liisa Ukkola-Vuoti,
  • Iiro Toppila,
  • Johanna Vikkula,
  • Jan Seppälä,
  • Kristiina Vuolukka,
  • Katja Marin,
  • Hanne Kuitunen,
  • Tatu Miettinen,
  • Anu Partanen

摘要

Hodgkin lymphoma (HL) is a B-cell neoplasm with a cure rate of 90%. Previous data on late morbidity in patients with HL cover the era of older treatment modalities. This real-world study consisted of 2912 patients diagnosed with HL between 2000 and 2019 in Finland and aimed to clarify the incidence of late-onset cardiopulmonary morbidity compared to matched controls. Patient data were collected from four nationwide Finnish healthcare registries. We reported a higher occurrence of coronary artery disease in patients aged < 50 years at diagnosis than in controls (RR 3.80 (2.16–6.74), p < 0001). Additionally, a higher incidence of both heart failure (RR 1.68 (1.28–2.21), p < 0.001) and valvular heart disease (RR 1.80 (1.17–2.78), p = 0.006) was detected in patients aged ≥ 50 years at diagnosis than in the controls. Remarkably, in the < 50 years age group, the incidences of pneumonia (RR 4.89 (3.58–6.71), p < 0.001) and pulmonary embolism (RR 7.78 (2.75–21.95), p < 0.001) were higher than those in the control group. In conclusion, with the current treatment modalities, late cardiopulmonary morbidity in long-term survivors remains a great challenge. A strategy for primary prevention and early detection of late toxicity remains crucial and a critical evaluation of current treatment practices is warranted.